Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04768296 · ClinicalTrials.gov registry record · Phase 2
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT04768296 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 76 participants.
The verdict
NCT04768296, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main part. The safety run-in part will be conducted in Japan.
Interventions
- DRUG Topotecan
- DRUG Berzosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04768296
The ClinicalTrials.gov registry entry for NCT04768296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT04768296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04768296 about?
NCT04768296 is a clinical study titled "Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)". The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main pa...
What is the current status of trial NCT04768296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2021-03-29. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT04768296?
The interventions under investigation include: Topotecan (DRUG), Berzosertib (DRUG).
Who is sponsoring clinical trial NCT04768296?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.